Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study

BACKGROUND: The ORAL Surveillance trial showed a potentially higher incidence of malignancy and major adverse cardiovascular events (MACEs) associated with tofacitinib than those associated with tumor necrosis factor (TNF) inhibitors (TNFis). However, few studies have compared the safety of non-TNFi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, Shuhei, Miyata, Masayuki, Suzuki, Eiji, Kanno, Takashi, Sumichika, Yuya, Saito, Kenji, Matsumoto, Haruki, Temmoku, Jumpei, Fujita, Yuya, Matsuoka, Naoki, Asano, Tomoyuki, Sato, Shuzo, Migita, Kiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586060/
https://www.ncbi.nlm.nih.gov/pubmed/37868999
http://dx.doi.org/10.3389/fimmu.2023.1267749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586060/
https://www.ncbi.nlm.nih.gov/pubmed/37868999
http://dx.doi.org/10.3389/fimmu.2023.1267749

Ejemplares similares